Search Results - "BLACKWELL, K. L"

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) by Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C.H., Bergh, J., Biganzoli, L., Blackwell, K.L., Cardoso, M.J., Cufer, T., El Saghir, N., Fallowfield, L., Fenech, D., Francis, P., Gelmon, K., Giordano, S.H., Gligorov, J., Goldhirsch, A., Harbeck, N., Houssami, N., Hudis, C., Kaufman, B., Krop, I., Kyriakides, S., Lin, U.N., Mayer, M., Merjaver, S.D., Nordström, E.B., Pagani, O., Partridge, A., Penault-Llorca, F., Piccart, M.J., Rugo, H., Sledge, G., Thomssen, C., van't Veer, L., Vorobiof, D., Vrieling, C., West, N., Xu, B., Winer, E.

Get full text

A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer by Burstein, H.J., Storniolo, A.M., Franco, S., Forster, J., Stein, S., Rubin, S., Salazar, V.M., Blackwell, K.L.

“…The efficacy and tolerability of the epidermal growth factor receptor/human epidermal growth factor receptor type 2 (HER2) tyrosine kinase inhibitor lapatinib…”
Get full text

Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens by Blackwell, K. L., Pegram, M. D., Tan-Chiu, E., Schwartzberg, L. S., Arbushites, M. C., Maltzman, J. D., Forster, J. K., Rubin, S. D., Stein, S. H., Burstein, H. J.

“…Background: This phase II study evaluated the efficacy and safety of lapatinib in patients with human epidermal growth factor receptor 2 (HER2)-positive…”
Get full text

Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification by Betof, A S, Rabbani, Z N, Hardee, M E, Kim, S J, Broadwater, G, Bentley, R C, Snyder, S A, Vujaskovic, Z, Oosterwijk, E, Harris, L N, Horton, J K, Dewhirst, M W, Blackwell, K L

“…Background: In early-stage breast cancer, adjuvant chemotherapy is associated with significant systemic toxicity with only a modest survival benefit…”
Get full text

Analysis of dermatologic events in patients with cancer treated with lapatinib by Lacouture, M. E, Laabs, S. M, Koehler, M, Sweetman, R. W, Preston, A. J, Di Leo, A, Gomez, H. L, Salazar, V. M, Byrne, J. A, Koch, K. M, Blackwell, K. L

“…Purpose Dermatologic events (DEs) in patients with cancer treated with lapatinib, a small-molecule dual tyrosine kinase inhibitor (TKI) of epidermal growth…”
Get full text

Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer by Wu, Y., Amonkar, M.M., Sherrill, B.H., O’Shaughnessy, J., Ellis, C., Baselga, J., Blackwell, K.L., Burstein, H.J.

“…Progression-free survival (PFS) was significantly longer for the lapatinib plus trastuzumab (L+T) arm than for L alone in a phase III, randomized, open-label…”
Get full text

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer by Hortobagyi, G.N., Stemmer, S.M., Burris, H.A., Yap, Y.S., Sonke, G.S., Paluch-Shimon, S., Campone, M., Petrakova, K., Blackwell, K.L., Winer, E.P., Janni, W., Verma, S., Conte, P., Arteaga, C.L., Cameron, D.A., Mondal, S., Su, F., Miller, M., Elmeliegy, M., Germa, C., O’Shaughnessy, J.

“…The phase III MONALEESA-2 study demonstrated significantly prolonged progression-free survival (PFS) and a manageable toxicity profile for first-line…”
Get full text

Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis by HARDEE, M. E, KIRKPATRICK, J. P, SHAN, S, SNYDER, S. A, VUJASKOVIC, Z, RABBANI, Z. N, DEWHIRST, M. W, BLACKWELL, K. L

“…Tumour hypoxia has been shown to increase mutation rate, angiogenesis, and metastatic potential, and decrease response to conventional therapeutics. Improved…”
Get full text

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer by Hortobagyi, G.N., Stemmer, S.M., Burris, H.A., Yap, Y.S., Sonke, G.S., Paluch-Shimon, S., Campone, M., Petrakova, K., Blackwell, K.L., Winer, E.P., Janni, W., Verma, S., Conte, P., Arteaga, C.L., Cameron, D.A., Mondal, S., Su, F., Miller, M., Elmeliegy, M., Germa, C., O’Shaughnessy, J.

Get full text

Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer by Wu, Y, Amonkar, M M, Sherrill, B H, O'Shaughnessy, J, Ellis, C, Baselga, J, Blackwell, K L, Burstein, H J

Get full text

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) by Cardoso, F, Costa, A, Norton, L, Senkus, E, Aapro, M, André, F, Barrios, C.H, Bergh, J, Biganzoli, L, Blackwell, K.L, Cardoso, M.J, Cufer, T, El Saghir, N, Fallowfield, L, Fenech, D, Francis, P, Gelmon, K, Giordano, S.H, Gligorov, J, Goldhirsch, A, Harbeck, N, Houssami, N, Hudis, C, Kaufman, B, Krop, I, Kyriakides, S, Lin, U.N, Mayer, M, Merjaver, S.D, Nordström, E.B, Pagani, O, Partridge, A, Penault-Llorca, F, Piccart, M.J, Rugo, H, Sledge, G, Thomssen, C, van’t Veer, L, Vorobiof, D, Vrieling, C, West, N, Xu, B, Winer, E

Get full text

Tamoxifen Inhibits Angiogenesis in Estrogen Receptor-negative Animal Models by BLACKWELL, Kimberly L, HAROON, Zishan A, SIGING SHAN, SAITO, Willfred, BROADWATER, Gloria, GREENBERG, Charles S, DEWHIRST, Mark W

“…Inhibition of tumor angiogenesis is a therapeutic strategy that can inhibit tumor growth and metastases. The aim of this study was to determine whether the…”
Get full text

Ultrasound guided pO2 measurement of breast cancer reoxygenation after neoadjuvant chemotherapy and hyperthermia treatment by Vujaskovic, Z, Rosen, E L, Blackwell, K L, Jones, E L, Brizel, D M, Prosnitz, L R, Samulski, T V, Dewhirst, M W

“…The objective of this study was to determine whether neoadjuvant chemotherapy in combination with hyperthermia (HT) would improve oxygenation in locally…”
Get more information

Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density by Blackwell, K L, Bostwick, D G, Myers, R P, Zincke, H, Oesterling, J E

“…The serum prostate specific antigen (PSA) level was determined in 311 men with documented prostate cancer (stages T1cN0, T2N0 and T3N0) before bilateral pelvic…”
Get more information

Manganese and epilepsy: brain glutamine synthetase and liver arginase activities in genetically epilepsy prone and chronically seizured rats by Carl, G F, Blackwell, L K, Barnett, F C, Thompson, L A, Rissinger, C J, Olin, K L, Critchfield, J W, Keen, C L, Gallagher, B B

“…Low blood manganese (Mn2+) concentration is associated with epilepsy in humans and rats. The low Mn2+ concentration is attributed by some investigators to the…”
Get more information

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer by Hortobagyi, Gabriel N, Stemmer, Salomon M, Burris, Howard A, Yap, Yoon-Sim, Sonke, Gabe S, Paluch-Shimon, Shani, Campone, Mario, Blackwell, Kimberly L, André, Fabrice, Winer, Eric P, Janni, Wolfgang, Verma, Sunil, Conte, Pierfranco, Arteaga, Carlos L, Cameron, David A, Petrakova, Katarina, Hart, Lowell L, Villanueva, Cristian, Chan, Arlene, Jakobsen, Erik, Nusch, Arnd, Burdaeva, Olga, Grischke, Eva-Maria, Alba, Emilio, Wist, Erik, Marschner, Norbert, Favret, Anne M, Yardley, Denise, Bachelot, Thomas, Tseng, Ling-Ming, Blau, Sibel, Xuan, Fengjuan, Souami, Farida, Miller, Michelle, Germa, Caroline, Hirawat, Samit, O’Shaughnessy, Joyce

“…In patients with advanced HR-positive, HER2-negative breast cancer, the addition of the cyclin-dependent kinase inhibitor ribociclib to letrozole was…”
Get full text

A clinical comparison of Grason Stadler insert earphones and TDH-50P standard earphones by BLACKWELL, K. L, OYLER, R. F, SEYFRIED, D. N

“…Recent investigations have reported numerous advantages of insert earphones. However, no data have been reported regarding Grason Stadler (GS) insert…”
Get full text

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer by Hortobagyi, G N, Stemmer, S M, Burris, H A, Yap, Y S, Sonke, G S, Paluch-Shimon, S, Campone, M, Petrakova, K, Blackwell, K L, Winer, E P, Janni, W, Verma, S, Conte, P, Arteaga, C L, Cameron, D A, Mondal, S, Su, F, Miller, M, Elmeliegy, M, Germa, C, O'Shaughnessy, J

Get full text

Symptom experiences and nonadherent medication-taking behaviors of breast cancer patients taking adjuvant hormone therapy by Shelby, R. A., Keefe, F. J., Red, S. N., Blackwell, K. L., Peppercorn, J. M., Marcom, P. K., Kimmick, G. G.

“…Abstract only…”
Get full text

EMILIA: A phase III, randomized, multicenter study of trastuzumab-DM1 (T-DM1) compared with lapatinib (L) plus capecitabine (X) in patients with HER2-positive locally advanced or metastatic breast cancer (MBC) and previously treated with a trastuzumab-based regimen by Verma, S., Dieras, V., Gianni, L., Miles, D., Welslau, M., Pegram, M. D., Baselga, J., Guardino, E., Fang, L., Linehan, C. M., Blackwell, K. L.

“…Abstract only…”
Get full text